Omid Beiki1,2,3, Paolo Frumento4, Matteo Bottai4, Ali Manouchehrinia1, Jan Hillert1. 1. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 2. Cognizant Technology Solutions, Stockholm, Sweden. 3. Kermanshah University of Medical Sciences, Kermanshah, Iran. 4. Institute of Environmental Medicine, Unit of Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Abstract
Importance: Clinicians' experience and findings from recent natural history studies suggest that multiple sclerosis (MS) may now be running a more slowly progressing course than before. Objective: To investigate whether the risk of reaching MS disability milestones has changed over the last decade in Sweden. Design, Setting, and Participants: A nationwide population-based retrospective cohort study. By April 2017, 12 512 patients with available information on demographics, MS phenotype, and date of MS onset and diagnosis were registered in the Swedish MS Registry of which 7331 patients with at least 2 recorded Expanded Disability Status Scale scores (EDSS) and diagnosed between January 1995 and December 2010 were included. No further exclusion criteria were applied. Patients were followed up until December 2016 with a median duration follow-up of 8.5 (interquartile range, 4.7-13.8) years. Statistical analysis began in April 2017. Main Outcomes and Measures: Patients were followed up from MS onset date to the date of sustained EDSS 3.0, 4.0, and 6.0. To handle interval-censored observations, a Weibull model was fit, and the change in the risk of EDSS 3.0, 4.0, and 6.0 over calendar years was estimated and hazard ratios (HRs) with corresponding CIs were calculated. Results: Of 7331 patients, 5196 (70.9%) were women, and the mean (SD) age at diagnosis was 38.3 (11.7) years. Adjusting for sex, number of clinic visits, diagnostic delay, and onset age, a 3% decrease per calendar year of diagnosis for the risk of sustained EDSS 3.0 (HR, 0.97; 95% CI, 0.96-0.97), a 6% decrease for the risk of EDSS 4.0 (HR, 0.94; 95% CI, 0.93-0.95), and a 7% decrease for the risk of EDSS 6.0 (HR, 0.93; 95% CI, 0.91-0.94) among patients with relapsing-onset MS was found. The trends were not significant for patients with progressive-onset MS (EDSS 3.0: HR, 1.01; 95% CI, 0.98-1.03; EDSS 4.0: HR, 1.00; 95% CI, 0.98-1.02; EDSS 6.0: HR, 1.00; 95% CI, 0.98-1.02). Conclusions and Relevance: Risk of reaching major disability milestones has significantly decreased over the last decade in patients with relapsing-onset MS in Sweden. Several factors could potentially be responsible for this observation. However, given that no change was seen in disability accrual of patients with progressive-onset MS and the absence of efficacious treatment option in this group, increased use of more efficacious disease-modifying treatments could be a possible driver of this change.
Importance: Clinicians' experience and findings from recent natural history studies suggest that multiple sclerosis (MS) may now be running a more slowly progressing course than before. Objective: To investigate whether the risk of reaching MS disability milestones has changed over the last decade in Sweden. Design, Setting, and Participants: A nationwide population-based retrospective cohort study. By April 2017, 12 512 patients with available information on demographics, MS phenotype, and date of MS onset and diagnosis were registered in the Swedish MS Registry of which 7331 patients with at least 2 recorded Expanded Disability Status Scale scores (EDSS) and diagnosed between January 1995 and December 2010 were included. No further exclusion criteria were applied. Patients were followed up until December 2016 with a median duration follow-up of 8.5 (interquartile range, 4.7-13.8) years. Statistical analysis began in April 2017. Main Outcomes and Measures: Patients were followed up from MS onset date to the date of sustained EDSS 3.0, 4.0, and 6.0. To handle interval-censored observations, a Weibull model was fit, and the change in the risk of EDSS 3.0, 4.0, and 6.0 over calendar years was estimated and hazard ratios (HRs) with corresponding CIs were calculated. Results: Of 7331 patients, 5196 (70.9%) were women, and the mean (SD) age at diagnosis was 38.3 (11.7) years. Adjusting for sex, number of clinic visits, diagnostic delay, and onset age, a 3% decrease per calendar year of diagnosis for the risk of sustained EDSS 3.0 (HR, 0.97; 95% CI, 0.96-0.97), a 6% decrease for the risk of EDSS 4.0 (HR, 0.94; 95% CI, 0.93-0.95), and a 7% decrease for the risk of EDSS 6.0 (HR, 0.93; 95% CI, 0.91-0.94) among patients with relapsing-onset MS was found. The trends were not significant for patients with progressive-onset MS (EDSS 3.0: HR, 1.01; 95% CI, 0.98-1.03; EDSS 4.0: HR, 1.00; 95% CI, 0.98-1.02; EDSS 6.0: HR, 1.00; 95% CI, 0.98-1.02). Conclusions and Relevance: Risk of reaching major disability milestones has significantly decreased over the last decade in patients with relapsing-onset MS in Sweden. Several factors could potentially be responsible for this observation. However, given that no change was seen in disability accrual of patients with progressive-onset MS and the absence of efficacious treatment option in this group, increased use of more efficacious disease-modifying treatments could be a possible driver of this change.
Authors: Jonatan Freilich; Ali Manouchehrinia; Mark Trusheim; Lynn G Baird; Sophie Desbiens; Ernst Berndt; Jan Hillert Journal: Mult Scler Date: 2017-05-08 Impact factor: 6.312
Authors: Ilya Kister; Eric Chamot; Gary Cutter; Tamar E Bacon; Vilija G Jokubaitis; Stella E Hughes; Orla M Gray; Maria Trojano; Guillermo Izquierdo; Francois Grand'Maison; Pierre Duquette; Alessandra Lugaresi; Pierre Grammond; Cavit Boz; Raymond Hupperts; Thor Petersen; Giorgio Giuliani; Celia Oreja-Guevara; Gerardo Iuliano; Jeannette Lechner-Scott; Roberto Bergamaschi; Maria Edite Rio; Freek Verheul; Marcela Fiol; Vincent Van Pesch; Mark Slee; Helmut Butzkueven; Joseph Herbert Journal: J Neurol Sci Date: 2012-04-14 Impact factor: 3.181
Authors: Sarah Burkill; Scott Montgomery; MohammadHossein Hajiebrahimi; Jan Hillert; Tomas Olsson; Shahram Bahmanyar Journal: Neurology Date: 2017-07-07 Impact factor: 9.910
Authors: Simon M Steinvorth; Christian Röver; Simon Schneider; Richard Nicholas; Sebastian Straube; Tim Friede Journal: Mult Scler Date: 2013-03-07 Impact factor: 6.312
Authors: R Zivadinov; M Zorzon; B Weinstock-Guttman; M Serafin; A Bosco; A Bratina; C Maggiore; A Grop; M A Tommasi; B Srinivasaraghavan; M Ramanathan Journal: J Neurol Neurosurg Psychiatry Date: 2009-01-23 Impact factor: 10.154
Authors: Natalie A Schwehr; Karen M Kuntz; Mary Butler; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter Journal: Mult Scler Date: 2019-07-29 Impact factor: 6.312
Authors: Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp Journal: Nervenarzt Date: 2021-07-23 Impact factor: 1.214
Authors: Le H Hua; Carrie M Hersh; Fan Tian; Ellen M Mowry; Kathryn C Fitzgerald Journal: Mult Scler Relat Disord Date: 2020-11-23 Impact factor: 4.339
Authors: Elisabeth G Celius; Heidi Thompson; Maija Pontaga; Dawn Langdon; Alice Laroni; Stanca Potra; Trishna Bharadia; David Yeandle; Jane Shanahan; Pieter van Galen; Nektaria Alexandri; Jürg Kesselring Journal: Patient Prefer Adherence Date: 2021-01-08 Impact factor: 2.711
Authors: Dalia Rotstein; Jacqueline M Solomon; Maria Pia Sormani; Xavier Montalban; Xiang Y Ye; Dina Dababneh; Alexandra Muccilli; Georges Saab; Prakesh Shah Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-10-12
Authors: Axel Petzold; Philipp Albrecht; Laura Balcer; Erik Bekkers; Alexander U Brandt; Peter A Calabresi; Orla Galvin Deborah; Jennifer S Graves; Ari Green; Pearse A Keane; Jenny A Nij Bijvank; Josemir W Sander; Friedemann Paul; Shiv Saidha; Pablo Villoslada; Siegfried K Wagner; E Ann Yeh Journal: Ann Clin Transl Neurol Date: 2021-05-19 Impact factor: 4.511